Skip to main content
. 2021 Dec 21;12(6):e02158-21. doi: 10.1128/mBio.02158-21

FIG 6.

FIG 6

Validation of inhibitors in S. flexneri infection of primary human macrophages (Mφ). (A) Schematic of inhibitor validation in S. flexneri ΔvirG infection cell models. (B) Effects of IRAK1 and PDHB inhibitors on the survival of primary human monocyte-derived macrophages (hMDMs) infected with S. flexneri, with host cell death measured by LDH release. (C) Effects of IRAK1 and PDHB inhibitors on the growth of intracellular S. flexneri ΔvirG in hMDMs, as measured by CFU. (D) Effects of the combination of IRAK1 and PDHB inhibitors (Combo) on the survival of hMDMs infected with one of two S. flexneri wild-type strains, S. flexneri M90T and S. flexneri 2457T, which were grown in TSB before infection. (E) Effects of the combination of IRAK1 and PDHB inhibitors on the growth of intracellular S. flexneri wild-type strains in hMDMs, as measured by CFU. IRAK1/4-Inh was used at 10 μM. Oxythiamine (OT) was used at 0.1 mM. Data represent the means ± SD (n = 4) (Student's two-tailed unpaired t test, *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). 6d, 6 days.